Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Study of an Investigational Drug for the Treatment of Major Depressive Episode Associated With Bipolar I Disorder.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Inclusion Criteria (not all inclusive):~* Subject provides written informed consent and is willing and able to comply with the protocol in the opinion of the Investigator.~* Subject is 18 to 65 years of age, inclusive, at the time of informed consent.~* Subject meets DSM-5 criteria, based on the SCID-5-CT, for bipolar I disorder, current episode depressed with or without rapid cycling disease course (≥ 4 episodes of mood disturbance but \< 8 episodes in the previous 12 months) with or without psychotic features.~* Subject's current major depressive episode is ≥ 4 weeks and less than 12 months in duration at Screening.~* Subject has a MADRS total score ≥ 22 at both Screening and Baseline.~* Subject has a CGI-BP-S depression score ≥ 4 at both Screening and Baseline.~* Subject has a YMRS total score ≤ 12 at both Screening and Baseline.~* Subject is in good physical health, based on medical history, physical examination, neurological examination, vital signs, ECGs, and results of clinical laboratory tests (hematology, chemistry, and urinalysis).~Exclusion Criteria:~Exclusion Criteria (not all inclusive):~* Subject currently has any DSM-5 defined psychiatric diagnosis other than bipolar I disorder that was the primary focus of treatment, or is currently being treated with concomitant medication~* Subject has a lifetime history of, or symptoms consistent with, schizophrenia, schizoaffective disorder, or a major psychiatric diagnosis other than bipolar I disorder that is judged to pose risk to the study scientific objectives~* Subject has a history of non-response to an adequate (6-week) trial of 3 or more antidepressants (with or without mood stabilizers) during the current major depressive episode.~* Subject has any clinically significant unstable medical condition or any clinically significant chronic disease that would pose a risk to the subject or that might confound the results of the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- SEP-4199 CR 200 mg (Type: EXPERIMENTAL): SEP-4199 CR 200 mg/day
- SEP-4199 CR 400 mg (Type: EXPERIMENTAL): SEP-4199 CR 400 mg/day
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).